AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06502652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance training
Description: The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
Study NCT06402682 — intervention group
Intervention type: PROCEDURE
Intervention: Right approach
Description: Right approach of the management of esophageal atresia with a right aortic arch
Study NCT06402682 — intervention group
Intervention type: PROCEDURE
Intervention: Left approach
Description: Left approach of the management of esophageal atresia with a right aortic arch
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection （18 weeks）
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab （18weeks）
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 3 Q2W or AUC1.5 QW intravenous infusion
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection （12 weeks）
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Epirubicin
Description: According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential CTX
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
Study NCT06227117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab （12weeks）
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
Study NCT05596292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality glasses
Description: The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
Study NCT05596292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early mobilization protocol
Description: Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
Study NCT05596292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization protocol
Description: Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
Study NCT06297655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human activated coagulation factor VIII for injection
Description: Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
Study NCT05099523 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: taking arterial blood sample through the injector
Description: taking blood samples from patients applied with different oxygen concentrations
Study NCT05099523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: taking arterial blood sample through the injector
Description: taking blood samples from patients applied with different oxygen concentrations
Study NCT05422352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
Study NCT05585931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg
Description: Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
Study NCT05585931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H Placebo
Description: Subjects were given Placebo with 240 mL warm water under fasting condition.
Study NCT05580055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Affinity
Description: Blood Analyser
Study NCT06296433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR rehabilitation
Description: VR software application containing education, exergames, therapeutic exercises and relaxation sections.
Study NCT06296433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VR video application
Description: VR software application that plays 2D nature videos
Study NCT06519552 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK008 Single intravenous infusion administration
Description: Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant.
Study NCT06065527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Map Our Life
Description: The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
Study NCT06065527 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
Study NCT05781971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein
Description: Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
Study NCT05781971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high protein
Description: Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
Study NCT05781971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
Study NCT05781971 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: rehabilitation
Description: In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
Study NCT05781971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: standard protein
Description: The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
Study NCT05781971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard protein
Description: The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
Study NCT05096871 — intervention group
Intervention type: GENETIC
Intervention: Genotyping by Real Time PCR
Description: 3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA).
Study NCT05237258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialty Palliative Care
Description: Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
Study NCT05842304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active cTBS
Description: Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
Study NCT05842304 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham cTBS
Description: Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
Study NCT06696638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT-guided Phigh settings during APRV
Description: The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.
Study NCT05237258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Palliative Care
Description: Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
Study NCT05544422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Timed Up & Go Test and 30second Chair-Stand Test'
Description: Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other.
Study NCT06697717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients
Description: The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., >0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen.
Study NCT06697717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT-Guided PEEP Titration in IAH and ARDS Patients
Description: The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes.
Study NCT04736706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study NCT04736706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study NCT04736706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet
Study NCT04736706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
Study NCT04736706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study NCT04736706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study NCT05588193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVO
Description: post-visit outreach
Study NCT05588193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSH
Description: tele-sexual health visit during the ED visit
Study NCT05917366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
Study NCT05917366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
Study NCT05857319 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nutritional Psycho-Behavioral Reeducation Program
Description: The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program.
Study NCT05917366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coccyx Manipulation
Description: Application of manipulation to relax the levetor ani muscle
Study NCT05608343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difamilast
Description: Off-white ointment containing active ingredient, petrolatum and other ingredients
Study NCT05608343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Difamilast (Study drug) ointment without active ingradient
Study NCT04137133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: collection
Description: bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
Study NCT05339724 — intervention group
Intervention type: OTHER
Intervention: platelet count and mean platelet volume are obtained from whole blood count
Description: The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
Study NCT05256056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: efficacy of bupivacaine in different volumes
Study NCT05150756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
Description: At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
Study NCT05150756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulphate (10mg/ ml ampoule)
Description: At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
Study NCT06102525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Study NCT01161394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Study NCT01161394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone 30mg
Study NCT01161394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05766020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listen training
Description: Auditory skills with the inclusion of cognitive control.
Study NCT05329285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Alternative treatment
Study NCT06102525 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VGCV
Description: VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
Study NCT05826509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: Radical prostatectomy with lymph node dissection will be performed.
Study NCT05826509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative darolutamide + surgery.
Description: Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment.
Study NCT04932707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sub-occipital muscle inhibition technique
Description: this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
Study NCT04932707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization
Description: Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
Study NCT04932707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (passive stretch exercises)
Description: The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side